UPO Book

Brief Research Description

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the most common cause of chronic liver disease (CLD), and its advanced form, known as Metabolic dysfunction-associated steatohepatitis (MASH), has rapidly become one of the leading causes of cirrhosis and hepatocellular carcinoma (HCC). The global prevalence of MASLD is estimated to be around 25% and continues to rise because of obesity spreading, making MASLD a global health issue. Despite extensive research, there are still no approved therapies for treating MASH. Based on previous findings demonstrating an association between adaptive immune responses triggered by oxidative stress-derived antigens (OSAs) and MASH severity, the ongoing research activity deals with a) defining the relative contribution of B/T-lymphocytes in sustaining MASH-associated inflammatory responses, b) characterizing the immune mechanisms involved in MASH progression to cirrhosis and hepatocellular carcinoma (HCC), c) explore the possible therapeutic effects of interfering with immune responses in the setting of experimental MASH.

Keywords

Liver, MASH, MASLD, inflammation, immunity 

PubMed